RxDoctor Payments Data

Jennifer Duffy

Family · Albuquerque, NMNPI 1013687011

Payments from drug & device makers

$1,893in general payments, 2019–2025

Across 91 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$228
  • AbbVie$216
  • Daiichi Sankyo Inc.$193
  • Boston Scientific$157
  • Boehringer Ingelheim$148
  • Lilly USA, LLC$113
  • plus $838 from 19 others

What the payments were for

  • Food & beverage$1,87099%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,893 in reported general payments places this provider in the 85th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$25,898
Medicare patients
106
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide11$21,449
EliquisApixaban20$20,141
OzempicSemaglutide17$19,864
Levothyroxine Sodium178$1,802
Atorvastatin Calcium140$1,511
Gabapentin119$1,278
Tamsulosin Hcl72$1,146
Losartan Potassium99$1,106
Lisinopril117$1,095
Omeprazole54$1,059
Albuterol Sulfate HfaAlbuterol Sulfate36$982
Rosuvastatin Calcium80$975
Simvastatin60$725
Bupropion XlBupropion Hcl31$658
ProgesteroneProgesterone, Micronized16$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$113$21,44911 claims
PfizerEliquis$65$20,14120 claims
Novo NordiskOzempic$81$19,86417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →